A Look Ahead: Halozyme Therapeutics's Earnings Forecast
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) is set to release its quarterly earnings report on October 31, 2024. Analysts expect an EPS of $0.98. The company has a history of surpassing EPS estimates, which previously led to stock price increases. Analysts rate HALO as a 'Buy' with a price target suggesting a 23.42% upside. The company shows strong financial metrics, including a high net margin and ROE, but faces challenges with a high debt-to-equity ratio.
October 30, 2024 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics is expected to release its earnings report with an anticipated EPS of $0.98. The company has a history of beating estimates, which has previously led to stock price increases. Analysts rate the stock as a 'Buy' with a potential 23.42% upside.
The upcoming earnings report is highly relevant to Halozyme's stock price, as past performance shows a positive correlation between beating EPS estimates and stock price increases. The 'Buy' rating and significant upside potential further suggest a positive short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100